Regulatory Novartis secures pair of regulatory wins for skin disease and malaria treatments Pharmaceutical TechnologyNovartis' Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaceutical Technology Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: New NIHR-funded TRC for Parkinson’s diseaseNext: Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
